CA-CAVLI-WIRELESS
28.2.2023 11:12:37 CET | Business Wire | Press release
Cavli Wireless is set to attend the Embedded World 2023 edition in Nuremberg, Germany, from March 14-16, 2023. The event is known for being the largest trade fair for Embedded technology, showcasing various electronic systems, distributed intelligence, IoT, energy efficiency, and more. Cavli will showcase its IoT connectivity solutions in Hall 3, Booth 3-328.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005787/en/
Introducing The Cavli C16QS - The World's Most Affordable LTE CAT1.bis Cellular IoT Module @ EW23 (Graphic: Business Wire)
The premier showcase at the Cavli booth will be the newly launched Cavli C16QS, an integrated single-mode LTE CAT1.bis Cellular Module based on 3GPP Release 14, which comes with an integrated eSIM and GNSS. The Cavli C16QS will also offer OEMs implementing IoT to cut down initial hardware costs due to the efficient pricing of the module, which makes it the world’s most affordable LTE CAT1.bis solution in the market. The integrated eSIM coupled with Cavli Hubble Global Connectivity ensures the module can be deployed globally, making it an ideal solution for logistics, automotive, vehicle tracking, and much more.
The Hubble Stack Intelligence enables remote diagnosis, monitoring, and debugging of the C16QS through Hubble Lens, an advanced remote diagnosis feature of the Cavli Hubble IoT platform. This feature eliminates the need for physical intervention, making it possible to scale IoT efficiently. And through its robust operator partnerships in the EU, Cavli has achieved an extensive presence across Europe with its local LTE and LTE-M connectivity solutions, setting new industry standards in service quality and pricing.
Cavli Wireless will also be exhibiting the flagship C-Series Cellular IoT modules featuring LPWAN and Wideband connectivity with a wide range of options in terms of footprint, power consumption, and network capabilities, which makes Cavli Smart Modules an apt choice for any solution customers wish to implement. The Cavli solution expertise team will also be featuring live demos of the Hubble Tech Stack and free solution consulting to the booth visitors. The attendees can book a meeting with the consulting team here: https://www.cavliwireless.com/engagements/product-and-solution-guides.html
"As the primary trade event for technology companies worldwide, Embedded World 2023 provides the perfect platform for unveiling our industry-leading Cellular IoT solutions. Cavli Wireless is excited to join industry leaders in this prestigious event and demonstrate our commitment to democratizing the Internet of Things," commented, Tarun Thomas George, Chief Operating Officer, Cavli Wireless.
About Cavli Wireless
Cavli Wireless is a cellular IoT module manufacturer that combines IoT connectivity and data management into one platform. Cavli designs and manufactures industrial-grade cellular IoT smart modules that improve equipment reliability and expedite application development processes. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users with affordable global data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.
About Embedded World
Every year, the Embedded world Exhibition&Conference in Nuremberg offers the embedded community the opportunity to find out about innovations, exchange ideas, and maintain and establish valuable contacts. Exhibitors present state-of-the-art on all facets of embedded technologies, from components, modules, and complete systems to operating systems and software, hardware and software tools, and services related to embedded systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005787/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom